natgillin/translations-raw huggingface dataset:
The genetically modified dermal micro-organ of any one of claims 1-3, wherein said at least one recombinant gene product is not naturally produced by the organ from which the dermal micro-organ is derived. 
Genetički modificiran dermalni mikroorgan iz bilo kojeg od patentnih zahijeva 1 - 3, naznačen time, da najmanje jedan navedeni rekombinantni genski produkt nije prirodno proizveden u organu iz kojeg dermalni mikroorgan potječe.
The compound for use of claim 3. wherein the compound is used in a therapeutically effective amount ranging from 0.1 mg/kg to 300 mg/kg. 
Spoj za primjenu u skladu s patentnim zahtjevom 3, naznačen time, da se spoj koristi u terapijski učinkovitoj količini od oko 0,1 mg / kg do oko 300 mg / kg.
MTBE (3×25 mL) was added and the reaction mixture was concentrated to dryness after each addition to finally give 3.7068 g foam. 
MTBE (3x25 mL) je bio dodan i reakcijska smjesa je bila koncentrirana do suhoće nakon svakog dodavanja da bi se na kraju dobilo 3.7068 g pjene.
The carrier of claim 9, wherein the layers are made of metal foils selected from the group consisting of aluminium, tin, iron, zinc and magnesium. 
Nosač prema zahtjevu 10, gdje su slojevi napravljeni od metalnih folija izabranih iz skupine koja obuhvaća aluminij, kositar, željezo, cink i magnezij.
The processing system 7 is capable of precisely controlling the receiving, the preservation and the releasing of the bags by means of the cell codes; in fact, this system knows the contents of the various cells. 
Sustav za obradu 7 može precizno upravljati sa preuzimanjem, čuvanjem i izdavanjem vrećica uz pomoć kodova ćelija; u stvari, ovaj sustav prepoznaje sadržaje različitih ćelija.
A propulsion unit according to claim 1, wherein the longer stay (16 a) exhibits a larger inner volume than the other stays (16) to allow larger supply of lubrication means to hub (14) and bearing devices. 
Propulzijska jedinica prema zahtjevu 7, naznačena time, da podupirač (16a) ima veći unutrašnji volumen nego podupirači (16) za preostale dijelove, kako bi se omogućila opsežnija dostava mazivnog sredstva na glavčinu (14) 1 na nosive uređaje.
means (7, 16) for transmitting information indicative of said second time interval (T1) from said second location (200) to said reference location (100). 
sredstva (7, 16) za prijenos informacija indikativnih za navedeni drugi vremenski interval (T1) od navedene druge lokacije (200) do navedene referentne lokacije (100).
Immunoglobulin according to any of claims 1 to 8, characterised in that said modification is within a human variable domain at one of the amino acid positions within the amino acid sequence selected from the group consisting of amino acids 8 to 20, amino acids 44 to 50, amino acids 67 to 76 and amino acids 89 to 101, where the numbering of the amino acid position of the domains is that of the IMGT. 
Postupak u skladu sa zahtjevom 15 ilil6, naznačen time, da imunoglobulin obuhvaća neko od podučja strukturne petlje varijabilne domene koja sadrže modifikaciju u jednom vanjskom aminokiselinskom položaju unutar aminokiselinske sekvence izabrane iz skupine koju čine aminokiseline 8 do 20, aminokiseline 44 do 50, aminokiseline 67 do 76 i aminokiseline 89 do 101, pri čemu je numeriranje prema IMGT.
= R3 = H or R2 and R3 together form a cyclic boronate or borate ester; X is a helping group selected from the group consisting of i) a five or six membered heterocyclic aromatic ring comprising at least one N-atom being a part of an imine-group, wherein said N-atom forms the point of connection to the cyclohexapeptide ring, and ii) tetrazolyl for which a nitrogen atom forms the point of connection to the cyclohexapeptide ring, with 1,2-diaminoethane to obtain a compound of formula VIII or a pharmaceutically acceptable salt thereof and 
X je pomoćna skupina odabrana iz skupine koja sadrži i) petili šest člani heterociklički aromatski prsten koji sadrži barem jedan N-atom koji je dio iminske- skupine, pri čemu navedeni N-atom tvori točku spajanja na cikloheksapeptidni prsten, i 5 1i) tetrazolil za koji atom dušika tvori točku spajanja na cikloheksapeptidni prsten, sa 1,2-diaminoetanom da se dobije spoj sa formulom VIII ili njegove farmaceutski prihvatljive soli i b) proizvoljno izolaciju spoja sa formulom VIII ili njegove farmaceutski prihvatljive soli kako je dobiveno u koraku a).
has a polynucleotide sequence having at least 99% identity to SEQ ID NO 1 or SEQ ID NO 3 or having the polynucleotide sequence shown as SEQ ID NO 1 or SEQ ID NO 3. The host cell for use according to any preceding claim, wherein the disorder is selected from the group consisting of rheumatoid arthritis, psoriasis, multiple sclerosis, type I diabetes, coeliac disease, atopic dermatitis, rhinitis, irritable bowel syndrome (IBS), colitis, inflammatory bowel disorder (IBD), ulcerative colitis, pouchitis, Crohn's disease, functional dyspepsia, atopic diseases, necrotising enterocolitis, and combinations thereof. 
Roseburia flagelin, i/ili polinukleotidna sekvenca, i/ili vektor, i/ili stanica domaćin, uključujući bakteriju, koja sadrži navedeni vektor, i/ili stanica domaćin, uključujući bakteriju, koja sadrži navedenu polinukleotidnu sekvencu, za upotrebu prema patentnom zahtjevu 1, naznačena time da je navedeni poremećaj iz skupine koja sadrži reumatoidni artritis, psorijazu, multiplu sklerozu, dijabetes tipa 1, celijakiju, atopijski dermatitis, rinitis, sindrom nadraženih crijeva (IBS), kolitis, upalnu bolest crijeva (IBD), ulcerativni kolitis, Pouchitis (upala ilealnog spremnika), Crohnovu bolest, funkcionalnu dispepsiju, atopijske bolesti, nekrotizirajući enterokolitis, i njihove kombinacije.
The method of embodiment 11, wherein the pathology is selected from dystonia, extrapyramidal effects, dysphagia, rigidity and/or stiffness of limbs, choreoathetosis, tremor, dementia, spasticity, muscle weakness, and seizure. 
Spoj u skladu s patentnim zahtjevom 7, naznačen time što se patologiju bira između distonije, ekstrapiramidalnih učinaka, disfagije, krutosti i/ili ukočenosti udova, koreoatetoze, tremora, demencije, spazama, mišićne slabosti, te napadaja.
The pharmaceutical composition of Claim 7 wherein the acetylcholinesterase inhibitor is donepezil hydrochloride. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 7, naznačen time, da je inhibitor acetilkolinesteraze donepezil hidroklorid.
The method of claim 13, wherein the at least one of the at least two pump segments comprises a first pump segment and wherein the at least one other pump segment comprises a second pump segment and wherein respective peaks of the pulses provided through the first pump segment and the second pump segment are approximately 180 degrees out of phase. 
Postupak prema zahtjevu 11, naznačen time, da prema kojem barem jedan od najmanje dva segmenta (103) sisaljke sadrži prvi segment (103) sisaljke i gdje barem jedan od sljedećeg segmenta sisaljke sadrži drugi segment (103b) sisaljke 1 pri čemu su odgovarajuće vršne vrijednosti pulseva (601a, 601b) dobivenih kroz prvi segment sisaljke i drugi segment sisaljke otprilike 180 stupnjeva izvan faze.
Number of Animals Group 1 
Broj međunarodne objave:
The mixtures according to the invention, or the herbicidal compositions comprising them, can be employed, for example, in the form of directly sprayable aqueous solutions, powders, suspensions, also highly-concentrated aqueous, oily or other suspensions or dispersions, emulsions, oil dispersions, pastes, dusts, materials for spreading or granules, by means of spraying, atomizing, dusting, spreading or pouring. 
Smjese prema izumu, ili herbicidne kompozicije koje ih sadrže, mogu biti korištene, na primjer, u obliku direktno raspršivih vodenih otopina, prašaka, suspenzija, također visoko koncentriranih vodenih, uljnih ili drugih suspenzija ili disperzija, emulzija, uljnih disperzija, pasta, praha, materijala za prekrivanje ili granula, putem prskanja, atomizacije, prašenja, prekrivanja ili zalijevanja.
The process as claimed in claim 1 further comprising the steps of isolating and crystallising the compound of formula (I). 
Postupak kako je prijavljen u patentnom zahtjevu 1, naznačen time da nadalje obuhvaća korake izolacije i kristalizacije spoja formule (I).
an optical attitude sensor comprising a lighting system adapted to project a grid-like pattern of light, towards a surface and a light detector adapted, in use, to interpret the grid-like pattern in its field of view to ascertain a distance from the surface and an attitude of the system relative to the surface, the optical attitude sensor comprising a depth sensor adapted to determine points with distance at various positions in its field of view; 
senzor optičkog položaja (30), koji sadrži sustav za osvjetljavanje, prilagođen za projiciranje rešetkastog uzorka svjetla (32), prema površini i detektor svjetla, prilagođen, prilikom upotrebe, za interpretiranje rešetkastog uzorka (32) u svom vidnom polju radi određivanja udaljenosti od površine i položaja sustava (10) u odnosu na površinu, gdje je senzor optičkog položaja, koji sadrži senzor dubine, prilagođen za određivanje točaka čije su udaljenosti na različitim položajima u svom vidnom polju;
A compound as claimed in any one of claims 1-12, or a pharmaceutically acceptable salt, solvate, or prodrug thereof for use in the treatment of stroke, neuronal damage resulting from head trauma, epilepsy, seizures, neuronal loss following global and focal ischemia, pain, migraine, primary erythromelalgia, paroxysmal extreme pain disorder, cerebellar atrophy, ataxia, mental retardation, a neurodegenerative disorder, manic depression, tinnitus, myotonia, a movement disorder, or cardiac arrhythmia, or providing local anesthesia in a mammal, comprising administering an effective amount of said compound to a mammal in need of such treatment and wherein preferably said use is for treating pain and, wherein even more preferably said use is for preemptive or palliative treatment of pain; or ii) said pain is selected from the group consisting of chronic pain, inflammatory pain, neuropathic pain, acute pain, and surgical pain. 
Tvar u skladu s bilo kojim od patentnih zahtjeva 1-12, ili njena farmaceutski prihvatljiva sol ili solvat, za uporabu u liječenju moždanog udara, neurološkog oštećenja nastalog uslijed traume glave, epilepsije, konvulzija, gubitka neurona nakon globalne i fokalne ishemije, boli, migrene, primarne eritromelalgije, paroksizmalnog ekstremnog poremećaja boli, cerebelarne atrofije, ataksije, mentalne retardacije, neurodegenerativnog poremećaja, manične depresije, tinitusa, miotonije, poremećaja pokretanja, srčane aritmije, ili davanja lokalne anestezije sisavcima, obuhvaćajući primjenu učinkovite količine navedene tvari sisavcima koji imaju potrebu za takvim liječenjem 1 gdje je poželjna od navedenih uporaba tretiranje boli i gdje je još poželjnija i) - navedena uporaba prvotno ili palijativno liječenje boli; ili ii) navedena uporaba je odabrana 1z grupe koja se sastoji od kronične boli, upalne boli, neuropatske boli, akutne boli i kirurške boli.
(xviii) substitution therapy in innate primary suprarenal insufficiency, acquired primary suprarenal insufficiency, innate secondary suprarenal insufficiency, acquired secondary suprarenal insufficiency, emesis, which coincide with inflammatory, allergic and/or proliferative processes, 
(xviii) supstitucijske terapije kod urođene primarne nadbubrežne insuficijencije, stečene primarne nadbubrežne insuficijencije, urođene sekundarne nadbubrežne insuficijencije, stečene sekundarne nadbubrežne insuficijencije, (xix) emeza, koje se poklapaju s upalnim, alergijskim i/ili proliferativnim procesima,
is used for reaction, the formyl group being introduced at position 1 to yield a compound of formula (IV): 
sa e reagira, pri čemu se skupina formila uvodi na položaj 1 kako bi se dobio spoj formule (TV):
The resulting mixture is diluted with water (100 ml) and the organic portion is separated and dried over NaOH pellets for 5 minutes. 
Dobivenu smjesu se razrijedi svodom (100 ml) 1 organski dio se odvoji 1 suši se 5 minuta preko pilula NaOH.
The present invention further relates to a pharmaceutical formulation in a solid and liquid form containing a therapeutically effective amount of pentadecapeptide salt of the present invention for oral, intravenous, rectal, vaginal, intramuscular, local and other use. 
Farmaceutski pripravak, naznačen time, da so nalazi u krutom 1li tekućem obliku za oralnu, intravenoznu, rektalnu, vaginalnu, intramuskularnu, lokalnu 1 ostale primjene, pri čemu on obuhvaća terapeutski učinkovitu količinu soli pentadekapeptida opće formule (1) u skladu sa zahtjevima 112.
A method according to claim 1, wherein the pre-expanded polymer beads are preheated before placing them into the casting mould. 
Postupak prema zahtjevu 1, naznačen time što se pred-ekspandirane polimerne kuglice prethodno zagrijavaju prije nego se uvode u kalup za lijevanje.
reacting the compound of formula (I) and the compound of formula (II) together in a suitable anhydrous solvent and in the presence of a suitable catalyst, whereby the compound of formula (III) is obtained, characterized in that said catalyst is selected from the group comprising a salt of an aliphatic sulphonic acid and/or the salt of a optionally substituted aromatic sulphonic acid. 
međusobnom reakcijom spoja s formulom (I) i spoja s formulom (II) u pogodnom bezvodnom otapalu i u prisutnosti prikladnog katalizatora, pri čemu se dobiva spoj s formulom (III), naznačen time da navedeni katalizator je sol alifatske sulfonske kiseline ili sol fluorirane alifatske sulfonske kiseline.
In addition, GSK3B may find application in the treatment of other diseases such as: non-insulin dependent diabetes (such as diabetes type II) and obesity; manic depressive illness; schizophrenia; alopecia; cancers such as breast cancer, non-small cell lung carcinoma, thyroid cancer, T or B-cell leukemia and several virus-induced tumors. 
Uz to, GSK3B bi mogao naći primjenu u liječenju i drugh bolesti, poput: dijabetesa neovisnog o inzulinu (poput dijabetesa tip II) i pretilosti; manično-depresivne bolesti; shizofrenije; alopecije; raka, poput raka dojke, karcinoma velikih stanica pluća, raka štitnjače, leukemije T- ili B-stanica, te nekih tumora uzrokovanih virusima.
a transmitting section configured to transmit the generated downlink control information (813) The base station apparatus according to claim 1, wherein the portion of bits are LSBs Least Significant Bits, of the resource allocation information. 
Uređaj za prijenos prema zahtjevu 1, naznačen time da su dio bitova potrebnih za označavanje dodijeljenog pluraliteta klastera LSB-ovi, Najmanje Bitni Bitovi, podatka o dodjeli resursa.
The method of claim 9, wherein the treatment results in reducing the frequency of relapses in the human patient by 30% or more as compared to placebo in a human population. 
Lijek za uporabu prema bilo kojem od patentnog zahtjeva 1 ili patentnih zahtjeva 3-8, naznačen time, da jest za uporabu u smanjivanju učestalosti relapsa kod pacijenta koji pati od relapsno remitirajuće multiple skleroze.
Statistical analysis of the frequency of aberrant cells (structural or numerical) was performed using the Fisher's exact test. 
Statistička analiza frekvencije aberantnih stanica (strukturno ili brojčano) izvedena je primjenom Fisher-ovog točnog testa.
The method according to claim 6, wherein said cancer is a WEE1 kinase associated cancer selected from the group consisting of breast cancer, lung cancer, pancreatic cancer, colon cancer, ovarian cancer, acute leukemia, chronic lymphatic leukemia, chronic myelocytic leukemia, and Hodgkin's lymphoma. 
Inhibitor WEE1 za upotrebu prema patentnom zahtjevu 6, gdje navedeni karcinom predstavlja karcinom povezan sa WEE1 kinazom odabran iz grupe koja se sastoji od karcinoma dojke, karcinoma pluća, karcinoma pankreasa, karcinoma debelog crijeva, karcinoma jajnika, akutne leukemije, kronične limfatične leukemije, kronične mijelocitne leukemije i Hodkinovog limfoma.
wherein R<4a> is a phenyl group substituted by a halogen atom, a cyano group, a C1-6 alkyl group, a halo-C1-6 alkyl group, a C1-6 alkoxy group, a halo-C1-6 alkoxy group, and a mono- or di-C1-6 alkylamino group; or a heterocyclyl group substituted by a halogen atom, a cyano group, a C1-6 alkyl group, or a C1-6 alkoxy group; 
S. _R rI Sa R gdje R* je fenilna skupina, supstituirana s atomom halogena, cijano skupinom, alkilnom skupinom, halogenalkilnom skupinom, alkoksi skupinom, halogenalkoksi skupinom, alkilendioksi skupinom, alkilenoksi skupinom ili mono- ili di-alkilamino skupinom; ili heterociklilna skupina, supstituirana s atomom halogena, cijano skupinom, alkilnom skupinom, halogenalkilnom skupinom, alkoksi skupinom ili halogenalkoksi skupinom; a R* je atom vodika;
a circuit for receiving phase relation information; said circuit for transmitting said detected first phase relation being adapted to combine said first phase relation and said second phase relation and transmit said combined phase towards said remote location. 
- < aspomenuti krug za odašiljanje spomenutog otkrivenog prvog faznog odnosa je adaptiran da spaja spomenuti prvi fazni odnos i spomenuti drugi fazni odnos te da odašilje spomenutu spojenu fazu prema spomenutoj udaljenoj lokaciji.
A compound represented by formula (I) or a pharmaceutically acceptable salt thereof: 
Spoj predstavljen sa formulom (1) ili njegova farmaceutski prihvatljiva sol:
Example 2: Tablets by granulation process g of microcrystalline cellulose, 1920 g of lactose monohydrate, 840 g of corn starch and 250 g of hydroxypropylcellulose were homogenised in a high-shear mixer. 
Primjer 2: Tablete dobivene postupkom granulacije 5030 g mikrokristalne celuloze, 1920 g monohidratne laktoze, 840 g kukuruznog škroba 1 250 g hidroksipropilno celuloze bili su homogenizirani u sjeckajućem mikseru.
with a plurality of sensing positions (4) provided along a longitudinal extent of the key (1), 
s barem jednim mjestom za raspoznavanje (4), koje se nalazi uzdužno na ključu (1) C.
The shaped article according to any one of claims 1 to 6, wherein the elastomeric material has a density according to ISO 845 of less than 300 kg/m3, preferably less than 200 kg/m3, more preferably less than 150 kg/m3, and a thermal conductivity according to EN 12667 of less than 0.050 W/mK at 0°C, preferably less than 0.045 W/mK at 0°C, more preferably less than 0.040 W/mK at 0°C. 
Oblikovani članak (100) prema bilo kojem od zahtjeva 1 do 6, pri čemu elastomerni materijal ima gustoću prema ISO 845 manju od 300 kg/m3, po mogućnosti manju od 200 kg/m3, poželjnije manju od 150 kg/m3, i toplinsku vodljivost u skladu s EN 12667 manju od 0,050 W/mK pri 0°C, poželjno manju od 0,045 W/mK na 0°C, poželjnije manju od 0,040 W/mK na 0°C.
A neutralising antibody which binds human IL-17A and human IL-17F which has a binding affinity for IL-17F of better than 2nM and a binding affinity for IL-17A of better than 100pM as measured by surface plasmon resonance. 
PATENTNI ZAHTJEVI Neutralizirajuće protutijelo koje se veže za humani IL-17A i humani IL-17F naznačeno time da ima afinitet vezanja za IL-17 bolje nego 2 nM i afinitet vezanja za IL-17A bolje nego 100 pM kako je izmjereno sa površinskom rezonancom plazmona.
In a variation, the catalyst of step a) or b) further contains at least one dopant selected from boron and fluorine and a mixture of boron and fluorine. 
Postupak prema jednom od zahtjeva 1 do 3, naznačen time da katalizator 1z koraka a) ili b) nadalje sadrži barem jednu primjesu koja se bira od bora i fluora i smjese bora i fluora.
an expanding agent in an amount ranging from 1% to 10% by weight, calculated with respect to the sum of (a) + (b) + (c). 
sredstvo za širenje u količini u rasponu od 1 % do 10 % po masi, računato u odnosu na sumu (a) + (b) + (c).
No particular order of addition of the respective ingredients is required. 
Ne zahtijeva se neki određeni redoslijed dodavanja navedenih sastojaka.
The process of claim 1, wherein the fifth organic solvent is methyl t -butyl ether. 
Postupak prema patentnom zahtjevu 2, pri čemu je organsko otapalo korišteno u koraku iic, metil t-butil eter.
The print medium of claim 3, wherein the pigment has a specific surface area of greater than 25 m2/g, a d50 value from 0.3 to 3 µm and a porosity, when in form of a compacted bed, of greater or equal to 35 %. 
Tiskovna podloga prema zahtjevu 3, naznačena time da pigment ima specifičnu površinu veću od 25 m'/g, ds vrijednost od 0.3 do 3 um i poroznost, kada je u kompaktnom obliku, veću ili jednaku 35 %.
Use according to any one of claims 1 to 6, wherein said ionizing radiations are selected in the group consisting of X-Rays, Y-Rays, electron beams and radioisotope emissions. 
Uporaba prema bilo kojem od zahtjeva 1 1 4, ili nanočestice HfO, ili agregati nanočestica HfO, za uporabu prema bilo kojem od zahtjeva 2, 3 i 4, gdje su spomenuta ionizirajuća zračenja odabrana iz skupine koju čine X-zrake, y-zrake, elektronski snopovi i zračenja radioizotopa.
The composition according claim 1 further comprising at least one pharmaceutically or cosmetically acceptable vehicle, and/or at least one pharmaceutically or cosmetically acceptable excipient or adjuvant. 
Pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što dodatno sadrži najmanje jedan farmaceutski ili kozmetički prihvatljivi vehikulum, i/ili najmanje jednu farmaceutski ili kozmetički prihvatljivu pomoćnu tvar ili adjuvans.
In yet another embodiment, the invention provides a compound of Formula (5): 
Spoj, naznačen time, da ima formulu (5): ma
further comprising, prior to (c), computationally removing allele frequencies for polymorphisms identified has being homozygous in both the fetus and the pregnant individual; further comprising, prior to (c), computationally removing allele frequencies for polymorphisms identified has being heterozygous in the pregnant individual; 
Postupak prema patentnom zahtjevu 1, naznačen time što nadalje sadrži, prije postupka (c), računalno uklanjanje učestalosti alela za polimorfizme koji su identificirani kao homozigotni i kod fetusa i kod trudne osobe.
Enantiomerically pure compound of formula 1 
Enantiomerno čisti spoj formule 1 ci
The invention encompasses a series of pyrimidinone compounds which inhibit HIV integrase and thereby prevent viral integration into human DNA. 
Izum obuhvaća seriju spojeva pirimidinona koji inhibiraju HIV integrazu i tako sprečavaju integraciju virusa u humanu DNK.
wherein linear predictive coefficients of the immediately preceding frame are included in codes of the target frame, and the internal state calculation means utilizes the linear predictive coefficients for the linear predictive inverse filter. An audio signal decoding program for decoding an encoded audio signal generated from an audio signal using first decoding means operating under a linear predictive coding scheme and second decoding means operating under a coding scheme which is different from the linear predictive coding scheme, the audio signal decoding program causing a computer device to function as: 
Kompjutorski program za dekodiranje audio signala koji sadrži naredbe koje, kada ih se provodi na kompjutoru, uzrokuju da navedeni kompjutor dekodira kodirani audio signal uz pomoć prvog dekodera (24), koji radi prema linearnoj prediktivnoj shemi kodiranja, i drugi dekoder (25), koji radi prema shemi kodiranja koja se razlikuje od linearne prediktivne sheme kodiranja, naznačen time što program za dekodiranje audio signala uzrokuje da kompjutorski uređaj funkcionira kao:
The organic portions are separated and washed with water (2×50 ml), brine (50 ml), dried (MgS04) and concentrated in vacuo. 
Organski dijelovi se odvoje 1 isperu s vodom (2 x 50 ml, sa zas. otop. NaC1 (50 ml), osuše (MgSOy) 1 koncentriraju u vakuumu.